NewsRoom Articles - Page 30 of 207

WednesdayJun 12, 2024 10:00 am

Researchers Say Brain ‘Overgrowth’ Could Contribute to Autism Development

Researchers have always been stumped by why some kids with autism experience symptoms such as an inability to speak, social struggles, and developmental delay, while the milder symptoms of other individuals diagnosed with autism actually improve over time. Now, new research has determined that severe autism may be associated with overgrowth in the brain’s outer layer during the gestation period. For their research, investigators obtained blood stem cells from 10 children aged between one year of age and four years of age. Their objective was to develop 3D models of each child’s cortexes using lab cell cultures. Once this was…

TuesdayJun 11, 2024 10:30 am

HealthLynked Corp. (HLYK) CEO Provides $1 Million Financing to Speed Company’s Continued Success in Revolutionizing Healthcare Industry

HealthLynked CEO Dr. Michael Dent recently provided $1 million in financing to the company, expected to accelerate its growth and expand its offerings Under Dr. Dent’s leadership, the company has developed an expansive array of products and services, including a comprehensive healthcare platform that connects patients, healthcare providers, and medical facilities in a secure, more efficient and cost-effective manner The company’s services include online medical records storage, online appointment scheduling for doctors nationwide, telemedicine, patient engagement tools, an e-commerce platform for over 15,000 name-brand medical supplies, concierge patient support, nurse chat, a reward points program, and co-management of family members’…

MondayJun 10, 2024 10:00 am

Delays in Diagnosing MS Highlight Need for More Awareness, Research

A new report has called attention to the need to increase investment in multiple sclerosis (MS) research and boost awareness of the illness. The report, which was released on World Multiple Sclerosis Day, was produced by MS Australia. Currently, more than 30,000 Australians live with multiple sclerosis. This is a chronic illness that affects the spinal cord and brain. Researchers have observed that the number of individuals being diagnosed with this condition has been growing at an alarming rate. The study found that the average time from when a patient began presenting with the disease’s symptoms to diagnosis was almost…

MondayJun 10, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Is ‘One to Watch’

Recent Achievements Annovis Bio recently announced statistically significant data from its Phase II/III Alzheimer’s study, showcasing Buntanetap’s potential to improve cognition in patients with mild AD Annovis Bio recently announced last patient last visit in the Phase III study of Buntanetap in patients with early Parkinson’s disease and expects data announcement in June 2024, marking significant progress in expanding its therapeutic reach The company has solidified strategic partnerships to enhance its research capabilities and broaden its market reach Investment Considerations Unique Market Position: Annovis Bio is the only company developing a drug for both AD and PD that inhibits multiple neurotoxic…

FridayJun 07, 2024 10:00 am

NIH Researchers Unveil AI Tool to Predict Oncology Patients’ Response to Immunotherapy

Scientists at the National Institutes of Health have designed an artificial intelligence (AI) tool that can predict if a patient’s cancer will respond to immune checkpoint inhibitors using clinical data. This artificial intelligence model may assist physicians in determining whether immunotherapy medications are effective in the treatment of different cancers. To determine the effectiveness of their machine-learning model, the researchers carried out a proof-of-concept study led by scientists from Memorial Sloan Kettering Cancer Center and the National Cancer Institute’s Center for Cancer Research. Their model was built and assessed using data from independent data sets, including more than 2,800 patients…

WednesdayJun 05, 2024 10:30 am

Astrotech Corp. (NASDAQ: ASTC) Subsidiary, “1st Detect”, Focuses on Superior Narcotics Trace Detection For Airport and Other Security Sites

Astrotech Corporation Subsidiary 1st Detect Approved as GSA Vendor; Introduces Advanced Narcotics Trace Detection Technology 1st Detect has now received approval from the U.S. General Services Administration (“GSA”) as an authorized vendor for government-related applications 1st Detect recently introduced a state-of-the-art Narcotics Trace Detection (“NTD”) narcotics library, which is particularly useful for detection at points of entry and government agencies involved in combating the illicit drug trade 1st Detect's portfolio now includes the TRACER 1000, Explosives Trace Detection (“ETD”) and Narcotics Trace detection Astrotech (NASDAQ: ASTC), through its subsidiary 1st Detect, is revolutionizing narcotics and explosives trace detection. With recent…

WednesdayJun 05, 2024 10:00 am

How to Minimize E-Commerce Chargeback Losses

Merchants in e-commerce may benefit from learning how to minimize chargeback losses, especially as fraud is becoming more rampant. Chargeback refers to when money is returned to a customer after contesting a charge. Sometimes, customers may dispute the charge if they didn’t receive the product they wanted, but other times, they may do so to keep the product without having to part with their funds. Juniper Research 2023 projections show that losses incurred as a result of e-commerce fraud globally surpassed $48 billion. Additionally, a study by Kount, which surveyed its customers, determined that in 2021, companies incurred 2.3% revenue…

TuesdayJun 04, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Announces Updates on ACT-EAP for CNM-Au8(R) Compassionate Use

Clene announced significant updates to their NIH-funded Accelerating Access to Critical Therapies Expanded Access Program (ACT-EAP) for CNM-Au8(R) compassionate use in amyotrophic lateral sclerosis (“ALS”) Clene has optimized its manufacturing, operational, and personnel processes to expand the program’s capacity to accommodate up to 180 participants The ACT-EAP, a collaboration among Clene, Columbia University, and Synapticure, was funded by the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS), signed into law by Congress and President Biden in December 2021 Clene (NASDAQ: CLNN) and its subsidiary, Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to improving mitochondrial health and protecting…

MondayJun 03, 2024 10:00 am

Virginia Tech Clinical Trial Seeks End to Brain Cancer Surgery

Patients with brain cancer often undergo surgery to treat the disease because this is the recommended treatment for this particular cancer. This doesn’t mean that surgery is always an option, as treatments for patients are often prescribed by their primary care providers. A trial conducted at the Virginia-Maryland College of Veterinary Medicine (Virginia Tech) looked into whether noninvasive treatments would do away with surgery in the management of brain cancer. For their study, the researchers used dogs to test out the effectiveness of focused ultrasound therapy, in particular histotripsy, in getting rid of brain tumors. Lauren Ruger, a postdoctoral research…

MondayJun 03, 2024 8:45 am

HealthLynked Corp. (HLYK) Continues to Expand AI Capabilities

HealthLynked is at the forefront of revolutionizing global healthcare related solutions for patients, doctors, and related healthcare organizations Some of the company’s solutions, including the HealthLynked Network, Augmented Real-Time Interface, and the new AI chat feature, incorporate artificial intelligence capabilities to foster better patient outcomes for all The new AI chat feature is designed to assist patients in locating healthcare providers across the country using markers such as name, specialty, or location and significantly enhance the effectiveness of the HealthLynked Concierge Team in reducing wait times and offering 24/7 service to users HealthLynked continues to lead in the development of…